Valeant Pharmaceuticals

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Walmart and McKesson team up to buy generic drugs

Pharmalot By Ed Silverman

Valeant discounts on heart drugs may be a hard sell to some hospitals

Pharmalot By Ed Silverman

A failed Valeant battlecry: ‘We’re not like Turing in any way, shape or form’

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: China probing drug and device makers for antitrust violations

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Price increases on biologics diminish savings on biosimilars

Pharmalot By Ed Silverman

Hospitals remain skeptical about Valeant discounts on important heart drugs

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: ‘Valeant was a sewer,’ says Berkshire’s Munger

Pharmalot By Ed Silverman

Board overhaul, new probes disclosed in Valeant annual report

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Valeant plans to overhaul its board

Politics By Dylan Scott

Valeant officials, under fire, pledge to consider cutting drug prices

Pharmalot By Ed Silverman

Valeant may have a new chief executive, but its future remains dim

Business By Dylan Scott

Valeant ‘made mistakes’ in raising drug prices, outgoing CEO tells lawmakers

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Valeant CEO says he was too aggressive in raising drug prices

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Ackman to testify at Senate hearing on drug prices

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Valeant looks to sign Perrigo chief as its new CEO

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Little company makes big bet on discarded Roche drug

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: AstraZeneca may bid for Medivation

Politics By David Nather

Valeant CEO reaches deal with Senate committee, contempt charges on hold

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Court revives class action against Pfizer

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Biogen looks to sell off hemophilia drugs

Politics By David Nather

Senate committee moves to hold Valeant CEO in contempt